Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 4 of 116

  1. Aspirin

    United Therapeutics Europe Ltd

    Node Positive HER2 Negative Breast Cancer

    phase 3 small molecule terminated

    1 trial

  2. Atezolizumab

    Hoffmann-La Roche

    Melanoma

    phase 3 small molecule completed

    1 trial

  3. Atezolizumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  4. Atezolizumab

    Hoffmann-La Roche

    Urothelial Carcinoma

    phase 3 small molecule completed

    2 trials

  5. Atezolizumab

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  6. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

    LISATA THERAPEUTICS, INC.

    Stage IV Melanoma

    phase 3 mab terminated

    1 trial

  8. Avelumab

    Serono Europe Limited

    First Line Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  9. Azacitidine Combined With Venetoclax and ATRA group

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  10. B013+Nab-Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Triple Negative Breast Cancer (TNBC)

    phase 3 small molecule completed

    1 trial

  11. B9991046

    Pfizer Australia Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  12. BAY 1841788, TRIPTORELIN

    Ningbo Cancer Hospital

    Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

    phase 3 small molecule active

    1 trial

  13. BAY 3427080, BAY 3427080 60 mg capsules placebo

    Bayer AG

    Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  14. BCA101X301

    Bicara Therapeutics

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    phase 3 small molecule active

    1 trial

  15. BEATcc

    Ningbo Cancer Hospital

    Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    phase 3 small molecule active

    1 trial

  16. BEP(500)

    United Therapeutics Europe Ltd

    Stage I Testicular Non-Seminomatous Germ Cell Tumor

    phase 3 small molecule completed

    1 trial

  17. BEVACIZUMAB, ERLOTINIB

    Fondazione Telethon ETS

    Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. BGB-11417 for Previously Untreated Chronic Lymphocytic Leukemia

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  19. BGB-11417-302

    BEONE MEDICINES AUS PTY LTD

    relapsed or refractory mantle cell lymphoma (R/R MCL)

    phase 3 small molecule active

    1 trial

  20. BGB-11417-303CLL-RR1

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  21. BGB-11417-304

    BEONE MEDICINES AUS PTY LTD

    treatment-naive Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  22. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    2 trials

  23. BGB-16673-302

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphotic leukemia and Small Lymphocytic lymphoma

    phase 3 small molecule active

    1 trial

  24. BGB-16673-304

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

    phase 3 small molecule active

    1 trial

  25. BGB-3111-304

    BEONE MEDICINES AUS PTY LTD

    Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  26. BGB-3111-306

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  27. BGB-43395

    BEONE MEDICINES AUS PTY LTD

    HR+/HER2- Breast Cancer

    phase 3 small molecule active

    1 trial

  28. BGB-A317-290-LTE1

    BEONE MEDICINES AUS PTY LTD

    Solid tumors and hamatological malignancies

    phase 3 small molecule active

    1 trial

  29. BGB-A317-316

    BEONE MEDICINES AUS PTY LTD

    Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

    phase 3 small molecule active

    1 trial

  30. BGB-A317-A1217-302

    BeiGene

    Locally advanced, unresectable, or metastatic non small cell lung cancer

    phase 3 small molecule active

    1 trial

  31. BGJ398

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  32. BNT323-01

    BioNTech SE

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  33. BNT327-03

    BioNTech SE

    English First-line extensive-stage small-cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  34. BNT327-05

    BioNTech SE

    First line triple-negative breast cancer (TNBC)

    phase 3 small molecule active

    1 trial

  35. BNT327-06

    BioNTech SE

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  36. BO25323

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  37. BO28984

    Hoffmann-La Roche

    Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  38. BO29554

    Hoffmann-La Roche

    Advanced or metastatic Non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  39. BO40336

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  40. BO41843

    Hoffmann-La Roche

    ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

    phase 3 small molecule active

    1 trial

  41. BO42592

    Hoffmann-La Roche

    Non-squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  42. BO42777

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  43. BO42843

    Hoffmann-La Roche

    High-risk muscle-invasive bladder cancer

    phase 3 small molecule active

    1 trial

  44. BO42864

    Hoffmann-La Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  45. BO45217

    Hoffmann-La Roche

    KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 other active

    1 trial

  46. BOOG 2010-02 Stop&Go study

    Teva Pharma GmbH

    Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  47. BRADI ICO-2023-15

    CERO THERAPEUTICS HOLDINGS, INC.

    Brain metastases of cancer > brain radionecrosis

    phase 3 small molecule active

    1 trial

  48. BRCA-P/ABCSG 50

    Shanghai Reinovax Biologics Co.,LTD

    Prevention of breast cancer in women with a BRCA1 germline mutation

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.